360° SearchNetwork Hot Spots Trends Time Series

Aranesp

Type: Product

Name: Aranesp

First reported May 10 2013 - Updated May 10 2013 - 2 reports

Amgen Forms Joint Venture to Sell Vectibix in China

Amgen and Zhejiang Beta Pharma said today they will form a joint venture to commercialize Amgen’s metastatic colorectal cancer drug (mCRC) Vectibix® (panitumumab) in China.The venture will draw on Zhejiang’s strengths of maintaining China’s largest oncology ... [Published Genetic Engineering News - May 10 2013]

Entities: Vectibix, Amgen Inc, Joint Venture, Erbitux, China

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Amgen Inc

Drug firm reaches $11M settlement

New York state once again will benefit from a multimillion-dollar settlement with a drug company.Attorney General Eric Schneiderman announced that New York and 35 other states reached an $11 million settlement with Amgen Inc. The agreement resolves claims ... [Published Buffalo Law Journal - May 06 2013]

Entities: Medicaid, Amgen Inc, Drugs

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Amgen aims to restock its medicine cabinet

Biotechnology firm Amgen recently falls short of first-quarter sales targets but is confident many of the drugs it has in development will be approved. Amgen Inc. is a biotechnology company that develops medicines used in the treatment of cancer, kidney ... [Published Los Angeles Times - May 06 2013]

Entities: Amgen Inc, epoetin alfa, Drugs

First reported May 05 2013 - Updated May 05 2013 - 1 reports

Bikies go postal to smuggle drugs

OUTLAW bikies and organised crime gangs are smuggling record amounts of banned steroids and hormones into Australia. The Australian Customs and Border Protection Services is policing airport importing rings and international postal deliveries of illegal ... [Published Perth Now - May 05 2013]

Entities: Hormone, Peptide, Drugs, Organized Crime

First reported May 02 2013 - Updated May 03 2013 - 4 reports

Drug Manufacturer Agrees to Pay Medicaid More Than $14.7 Mil. . .

Drug Manufacturer Agrees to Pay Medicaid More Than $14.7 Million to Resolve Illegal Kickback Case --$603,000 Recovered for the Missouri Medicaid...Targeted News ServiceDrug Manufacturer Agrees to Pay Medicaid More Than $14.7 Million to Resolve Illegal ... [Published Equities.com - May 03 2013]

Entities: Medicaid, Drugs, Aranesp, Chris Koster, Amgen Inc

First reported May 02 2013 - Updated May 02 2013 - 1 reports

EPO Pills: A Challenge For Amgen And Johnson & Johnson

For the past two and a half decades Amgen (AMGN)Amgen's products are Epogen and Aranesp and Johnson & Johnson's product is Procrit in the US and Eprex overseas. Numerous competing products exist in Europe including Mircera from Roche, Retacrit by Hospira ... [Published Seeking Alpha - May 02 2013]

Entities: Erythropoietin EPO, FibroGen Inc, anemia

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Amgen CEOs Prosper Despite (or Because of) Continuing Ethical Questions

This is becoming a familiar narrative on Health Care Renewal : top health care leaders continue to enrich themselves while their organizations' behavior continues to raise ethical questions.For our latest example we return to the ongoing adventures of ... [Published Health Care Renewal - May 02 2013]

Entities: Amgen Inc, Aranesp, Drugs, Ethical, Health Care

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Amgen, Inc. (AMGN): What’s Its Next Catalyst?

Amgen, Inc. (NASDAQ: AMGN ) stock has been on a bit of a roller coaster lately. Shares are up 23% year to date, but 8% off the high set earlier this month before the company reported first-quarter earnings.It wasn’t prettyAdjusted earnings per share was ... [Published InsiderMonkey.com - May 02 2013]

Entities: Amgen Inc, Catalyst, Enbrel, HUMIRA, Drugs

First reported Apr 30 2013 - Updated May 01 2013 - 5 reports

Amgen to Pay $11 Million Nationwide Medicaid Settlement

Attorney General Peter F. Kilmartin announced Tuesday that Rhode Island, as part of a nationwide settlement against the drug manufacturer Amgen, Inc., has resolved allegations that the company violated certain state false claims acts, by reporting inflated ... [Published Coventry Patch - May 01 2013]

Entities: Amgen Inc, Medicaid, Drugs, Enbrel, Aranesp

First reported May 01 2013 - Updated May 01 2013 - 2 reports

New Jersey is Paid $600,000-Plus from Separate Settlements R. . .

New Jersey is Paid $600,000-Plus from Separate Settlements Resolving Allegations of Wrongdoing by Two Pharmaceutical ManufacturersTargeted News ServiceTRENTON, N.J., April 30 -- The New Jersey Attorney General issued the following news release:Attorney ... [Published Equities.com - May 01 2013]

Entities: Par Pharmaceutical, Megace, Megestrol acetate, Drugs, Aranesp

First reported Apr 30 2013 - Updated May 01 2013 - 1 reports

What News Will Drive Amgen Stock Next?

Keep track of the stocks that matter to you.Help yourself with the Fool's FREE and easy new watchlist service today. It wasn't prettyAdjusted earnings per share was up 22% year over year, but the long-term health of a biotech company is always going to ... [Published Motley Fool - Apr 30 2013]

Entities: Amgen Inc, watchlist, XGEVA, Biotechnology, Prolia

First reported Apr 29 2013 - Updated Apr 30 2013 - 3 reports

Attorney General Bondi and 35 Other Attorneys General Reach Nearly $11 Million Settlement with Amgen, Inc. Over False Claims

TALLAHASSEE, Fla.-Attorney General Pam Bondi today announced that Florida, along with 35 other attorneys general, have reached a nearly $11 million settlement with Amgen, Inc. resolving false claims allegations. Allegedly, Amgen violated state false claims ... [Published Noodls - Apr 30 2013]

Entities: Amgen Inc, Pam Bondi, Medicaid, Attorney General, Drugs

Quotes

"We have seen once again long buying on market weakness and investors are coming to the understanding that the AIM market is providing fantastic opportunities" said Atif Latif, director of trading at Guardian Stockbrokers

SMALL CAP MOVERS: AIM market providing 'fantastic opportunities' as investors 'buy the dips' [Published This Is Money - May 15 2013]

...Jim McDermott, Democrat from Washington state, in a statement. "Still, Medicare must be a smart shopper and not overpay for services, particularly as we find better ways to cut waste. Today's report confirms that we can absolutely find savings in Medicare without compromising quality."

Medicare Overpaid $529 Million for Anemia Drugs in 2011 - Report [Published Nasdaq - May 10 2013]

Scott Maguire, Xenetic’s chief executive, said: "With the commencement of this Phase III trial in Russia, ErepoXen is now the most advanced candidate in our portfolio, and with our double-digit royalty agreement with SynBio, we can now see the potential of a recurring revenue stream.”"

Xenetic Biosciences starts Phase III trial for ErepoXen [Published Proactive Investors Australia - May 10 2013]

"There are no excuses for ripping off New York state taxpayers and defrauding our Medicaid programs," Schneiderman said. "At a time when state budgets are already strained, I am committed to going after any company that rips off our taxpayers, no matter how big they are."

Drug firm reaches $11M settlement [Published Buffalo Law Journal - May 06 2013]

More Content

sort by: Date \| Relevance
Pro Te Solutio - Vol. 6 No. 1 February 2013 [Published JD Supra - May 22 2013]
New Routes in Drug Delivery [Published Pharmaceutical & Medical Packaging News - May 21 2013]
SMALL CAP MOVERS: AIM market providing 'fantast... [Published This Is Money - May 15 2013]
New Devices Target Home Injection Market [Published Pharmaceutical & Medical Packaging News - May 12 2013]
Proactive Investors Mid & Sml Cap Weekly Roundu... [Published Proactiveinvestors United Kingdom RSS feed - May 11 2013]
Amgen Chased By The Bubble [Published Investopedia - May 11 2013]
Amgen Forms Joint Venture to Sell Vectibix in C... [Published Genetic Engineering News - May 10 2013]
Medicare Overpaid $529 Million for Anemia Drugs... [Published Nasdaq - May 10 2013]
Xenetic Biosciences starts Phase III trial for ... [Published Proactive Investors Australia - May 10 2013]
Amgen forms joint venture in China to boost Vec... [Published PMLive - May 10 2013]
Xenetic Biosciences starts Phase III trial for ... [Published Proactiveinvestors United Kingdom RSS feed - May 09 2013]
Affymax Could Be The Best Reversal Play For 2013 [Published Seeking Alpha - May 07 2013]
Drug firm reaches $11M settlement [Published Buffalo Law Journal - May 06 2013]
Amgen aims to restock its medicine cabinet [Published Los Angeles Times - May 06 2013]
Bikies go postal to smuggle drugs [Published Perth Now - May 05 2013]
Drug Manufacturer Agrees to Pay Medicaid More T... [Published Equities.com - May 03 2013]
Drug Manufacturer Amgen Agrees To Pay Medicaid ... [Published Equities.com - May 03 2013]
Missouri Medicaid program recovers $603,000 fro... [Published St Louis Business Journal - May 02 2013]
EPO Pills: A Challenge For Amgen And Johnson & ... [Published BioPortfolio - May 02 2013]
EPO Pills: A Challenge For Amgen And Johnson & ... [Published Seeking Alpha - May 02 2013]
Amgen CEOs Prosper Despite (or Because of) Cont... [Published Health Care Renewal - May 02 2013]
Missouri share of Amgen settlement is $603,493 [Published South Carolina Enquirer-Herald - May 02 2013]
Amgen, Inc. (AMGN): What’s Its Next Catalyst? [Published InsiderMonkey.com - May 02 2013]
Amgen to Pay $11 Million Nationwide Medicaid Se... [Published Coventry Patch - May 01 2013]
New York to get $3.3M from drug maker [Published Fairfield Business Journal - May 01 2013]
New Jersey is Paid $600,000-Plus from Separate ... [Published Equities.com - May 01 2013]
AG Gansler Secures Agreement With Drug Maker Ov... [Published Equities.com - May 01 2013]
Par, Amgen settle with state over drug claims [Published North Jersey.com - May 01 2013]
BRIEF: Amgen pays $11 million to settle Medicai... [Published Equities.com - May 01 2013]
Amgen to pay $11 million in national settlement [Published LegalNewsLine.com - Apr 30 2013]

Blogs

sort by: Date \| Relevance
Amgen CEOs Prosper Despite (or Because of) Cont... [Published Health Care Renewal - May 02 2013] This is becoming a familiar narrative on Health Care Renewal : top health care leaders continue to enrich themselves while their organizations' behavior continues to raise ethical questions.For our latest example we return to the ongoing adventures of ...
Amgen settles kickback allegations for $24.9M [Published PharmaGossip - Apr 18 2013] Biotechnology company Amgen Inc. has agreed to pay $24.9 million to resolve charges under the False Claims Act that it was involved in a kickback scheme with long-term care pharmacy providers, the U.S. Department of Justice said.The settlement with Thousand ...
3 Healthcare Stock Stories for Wednesday Invest... [Published Wall St. Cheat Sheet - Apr 17 2013] Vivus ( NASDAQ:VVUS ): Closing price $12.16Vivus has announced that the FDA approved its amendment and modification to the Risk Evaluation and Mitigation Strategy for Qsymia (phentermine and topiramate extended-release) capsules CIV. The amendment was ...
3 Healthcare Stock Stories for Wednesday Invest... [Published Wall St. Cheat Sheet - Apr 17 2013] Vivus ( NASDAQ:VVUS ): Closing price $12.16 Vivus has announced that the FDA approved its amendment and modification to the Risk Evaluation and Mitigation Strategy for Qsymia (phentermine and topiramate extended-release) capsules CIV. The amendment ...
Last Rites? Affymax Says The End May Be Near [Published Pharmalot - Mar 19 2013] After recalling its only marketed drug after 19 cases of anaphylaxis, a serious and life-threatening allergic reaction that led to three patient deaths, Affymax is considering a sale, unwinding operations or bankruptcy. For now, 230 employees – or 75 ...

Press Releases

sort by: Date \| Relevance
Amgen Announces Top-Line Results Of Phase 3 Ara... [Published PR Newswire: Health - Jan 16 2013]